news

Pedro, COLOTAN Ph.D. Researcher at J&J Johnson Innovative Medicine, participated in the 2023 Johnson & Johnson Global Science Symposium, where Ph.D. and Postdoctoral fellows, from all parts of the world, gathered in Beerse (Belgium), between October 17th and 19th. He was awarded the “Best Outstanding Talk”, amongst all selected Ph.D. and Postdoctoral participants, for his oral presentation titled: “Human organotypic ...

Sydney Mwasambu, COLOTAN Early Stage Researcher and PhD student at Uppsala University in Prof. Daniel Globisch’s group, shared their recent developments of their chemoselective probe technology at the 3rd Nordic Metabolomics Society conference.

“Some individuals possess incredible potential – and the ability to harness it. One such person I greatly admire is Christel Bergström Christel is a professor, successful researcher, program director, collaborative dean, and entrepreneur – to mention a few of her professional roles. No matter how much she takes on, I am delighted that she is generous with her time when I ...

Wednesday 25 October, Marco Tjakra, COLOTAN Early Stage Researcher and PhD student at the Department of Pharmacy and SweDeliver, presented his research on drug dissolution, diffusion and absorption from the human colon with a focus on the role of the colonic mucus layer. It was a hybrid event as one of four half-time seminars organised by the SweDeliver national competence ...

Theodoros, COLOTAN PhD researcher at UCC, wins the Best Online Poster Award at CoMH Future Research Conference 2023 on his poster entitled “Exploring polysaccharide-based coating for triggering site-specific drug release in the colon: an in vitro and in vivo evaluation”. His research aims to shed light on how the colonic microbiome can be utilized to trigger specific drug release in the ...

Managing the clinical effects of drug-induced intestinal dysbiosis with a focus to antibiotics: challenges and opportunities L. Gnatzy, G. Ismailos, M. Vertzoni, C. Reppas Abstract The term “intestinal dysbiosis” is used for indicating change(s) of the intestinal microbiota which have been associated with the development of diseases and the deterioration of disease treatments in humans. In this review, documented clinical effects of ...

Physiologically based biopharmaceutics modeling of regional and colon absorption in humans C. Tannergren, H. Jadhav, E. Eckernäs, J. Fagerberg, P. Augustijns, E. Sjögren Abstract Colon absorption is a key determinant for successful development of extended release and colon targeted drug products. This is the first systematic evaluation of the ability to predict in vivo regional differences in absorption and the extent ...

Epithelial and microbial determinants of colonic drug distribution Rebekkah Hammar, Mikael E. Sellin, Per Artursson Abstract A dynamic epithelium and a rich microbiota, separated by multi-layered mucus, make up the complex colonic cellular environment. Both cellular systems are characterized by high inter- and intraindividual differences, but their impact on drug distribution and efficacy remains incompletely understood. This research gap is ...

What is the colon? How do we get the drugs in the colon? And many other questions are answered in this short video explaining what the COLOTAN researchers are working on.. With special thanks to Katharina Kopp (ESR4 in COLOTAN), who made this video happen!

Rebekkah Hammar won the poster award at the 12th Pharmaceutical Profiling in Drug Discovery and Development Symposium in Uppsala. Poster titled: 3D COLONOIDS AS INTESTINAL IN VITRO ADME MODELS REFLECTIVE OF NATIVE EPITHELIUM. You may also check out Rebekkah’s work in this new publication in the Journal of Neuroscience, entitled “Selective Serotonin Reuptake Inhibitors Within Cells: Temporal Resolution in Cytoplasm, ...